New cancer drug TJ101 enters first human trials for advanced tumors

NCT ID NCT07181473

Recruiting now Disease control Sponsor: Phrontline Biopharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial is testing TJ101, an experimental antibody-drug conjugate that delivers chemotherapy directly to cancer cells. It is for adults with advanced or metastatic solid tumors (lung, prostate, esophageal, and others) who have run out of standard options. The study aims to find the safest dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TJ101 (an antibody-drug conjugate that targets EGFR and B7H3, delivering a chemotherapy drug directly to cancer cells)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for advanced solid tumors like lung, prostate, and esophageal cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 200 participants, so the drug may not prove effective or may have significant side effects. The results may not apply to all patients or tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer esophageal cancer Esophageal Neoplasms lung cancer lung neoplasm neoplasm non-small cell lung carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER LUNG CANCER (NSCLC) PROSTATE CANCER SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Florida Cancer Specialists & Research Institute
RECRUITING

Orlando, Florida, 32827, United States
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, China
Oncology Consultants
RECRUITING

Houston, Texas, 77030, United States
Sarah Cannon Research Institute (SCRI)
RECRUITING

Nashville, Tennessee, 37203, United States
Shanghai East Hospital
RECRUITING

Shanghai, China
Sir Run Run Shaw Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China
Union Hospital of Tongji Medical College
NOT_YET_RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.